Objectives: To evaluate the feasibility, safety, and efficacy of implantation of the new Nit Occlud ASD-R® (NOASD-R) device for percutaneous closure of ostium secundum atrial septal defects (ASD-OS).
Sinus venosus atrial septal defect (SVASD) is located high in the atrial septum where the right superior vena cava (RSVC) enters the right atrium, and is commonly associated with partial anomalous pulmonary venous return of right upper pulmonary vein (RUPV) into RSVC. Transcatheter closure of such defects has not been described in the literature. We have developed an innovative technique to close this defect by transcatheter means. We present here a 35-year old patient with SVASD and anomalous drainage of RUPV in RSVC in whom we closed the defect along with rerouting of RUPV to left atrium (LA) using a 12 mm × 61 mm adventa V12 covered stent in the RSVC with good outcome. © 2014 Wiley Periodicals, Inc.
Background: Transcatheter valve-in-valve (VIV) implantation has emerged as a novel treatment option in patients with degenerated aortic bioprostheses and high surgical risk. However, VIV implantation in small aortic bioprostheses using first generation TAVI devices has frequently resulted in high postprocedural gradients and small effective orifice areas. Recently, an updated version of the self-expandable Medtronic CoreValve prosthesis, which is particularly suitable for small aortic annuli, has become available. We report on the feasibility and early results of VIV implantation using this novel device in a series of patients with degenerated small aortic bioprostheses.
Objective: To evaluate in-hospital and short-term outcomes of percutaneous mitral valve repair according to patients´ logistic EuroSCORE (logEuroSCORE) in a multicenter registry
Objective: The aim is to find predictors for a prolonged LOHS after MitraClip® implantation.
Objectives: We aimed to compare quality of life benefits of percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) with non-CTO PCI.
Objectives: To examine the success and complication rates in percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) caused by in-stent restenosis (ISR).
Objectives: To evaluate the outcomes and benefits of using the hybrid algorithm for chronic total occlusion (CTO) percutaneous coronary intervention (PCI).
Background: Spontaneous coronary artery dissection (SCAD) is an increasingly recognized nonatherosclerotic cause of acute coronary syndrome. The angiographic characteristics of SCAD are largely undetermined. The goal of this study was to determine the prevalence of coronary tortuosity in SCAD and whether it may be implicated in the disease.
Background: Drug-eluting balloons (DEB) may reduce infrapopliteal restenosis and reintervention rates versus percutaneous transluminal angioplasty (PTA) and improve wound healing/limb preservation.
Background: Mitral regurgitation (MR) is the most common valvular heart disease, and mitral valve surgery is the gold standard therapy for severe MR. Many patients with severe MR are not referred for surgery because of old age, comorbidities, or severe left ventricular dysfunction. Transcatheter mitral valve implantation may be a better therapeutic option for these high-risk patients with severe symptomatic MR
In this edition of the Journal, Cheung et al. 1 report 2 successful deployments of a catheter-mounted valve for treatment of severe functional mitral valve regurgitation. Both procedures used a novel bovine pericardial valve designed for mitral valve replacement, which was mounted on a self-expanding nitinol frame and advanced through the cardiac apex via surgical cut down. Because of the mitral valve’s intricate pathoanatomy and lack of a rigid landing zone, this transcatheter mitral valve prosthesis has a complex design, including anchoring mechanisms to prevent migration into the atrium during ventricular contraction. The prosthesis is not a symmetrical tube but conforms to the typical D-shape of the mitral valve annulus. In contrast, transcatheter aortic valve replacement (TAVR) prostheses have a simple, symmetrical design, with no need for ventricular anchors or specific orientation. Although prosthesis development and technical execution of transcatheter mitral valve replacement (TMVR) present unique challenges, these 2 patients with successfully deployed catheter mitral valves demonstrate that these challenges are not insurmountable. Cheung et al. are to be congratulated for their pioneering effort, which serves as a proof-of-concept for transcatheter replacement in the noncalcified mitral valve. This makes it probable that routine application of TMVR will be technically possible in the near future, leading the authors to question whether TMVR will revolutionize therapy for mitral valve disease, mirroring the course of TAVR.
Background: Stenosis of saphenous vein grafts (SVGs) after coronary artery bypass grafting (CABG) is common and often requires percutaneous coronary interventions (PCI) for treatment. However, data for the effectiveness of drug-eluting stents (DES) versus bare-metal stents (BMS) in SVG-PCI are unclear.
Almost 2.5 millennia ago, Hippocrates published his famous quote: “As to diseases, make a habit of 2 things—to help or to do no harm.” In modern medicine, this issue remains in the spotlight as new therapies are introduced into clinical practice. An excellent example of promising efficacy results being overshadowed by safety concerns was the introduction of drug-eluting stents (DES), which were intended to reduce the need for repeat vascularization. Initial enthusiasm about the increased efficacy of DES (1,2) soon gave way to safety concerns after the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) published a report of a possible late excess mortality risk with DES (3). Fortunately, these concerns were disproved by large studies with long-term follow-up that demonstrated the long-term safety and efficacy of DES
Background: Invasive assessment of coronary physiology (IACP) offers important prognostic insights in ST-segment elevation myocardial infarction (STEMI) but the dynamics of coronary recovery are poorly understood.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos